FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973Andreas R. Baudy, Simon‐Peter Williams|EJNMMI Research|2012Cited by 62